Restriction of SARS-CoV-2 replication by targeting programmed -1 ribosomal frameshifting.
Yu SunLaura AbriolaRachel O NiedererSavannah F PedersenMia M AlfajaroValter Vinícius Silva MonteiroCraig B WilenYa-Chi HoWendy V GilbertYulia V SurovtsevaBrett D LindenbachJunjie U GuoPublished in: Proceedings of the National Academy of Sciences of the United States of America (2021)
Translation of open reading frame 1b (ORF1b) in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requires a programmed -1 ribosomal frameshift (-1 PRF) promoted by an RNA pseudoknot. The extent to which SARS-CoV-2 replication may be sensitive to changes in -1 PRF efficiency is currently unknown. Through an unbiased, reporter-based high-throughput compound screen, we identified merafloxacin, a fluoroquinolone antibacterial, as a -1 PRF inhibitor for SARS-CoV-2. Frameshift inhibition by merafloxacin is robust to mutations within the pseudoknot region and is similarly effective on -1 PRF of other betacoronaviruses. Consistent with the essential role of -1 PRF in viral gene expression, merafloxacin impedes SARS-CoV-2 replication in Vero E6 cells, thereby providing proof-of-principle for targeting -1 PRF as a plausible and effective antiviral strategy for SARS-CoV-2 and other coronaviruses.